Search results

  1. E

    Preprint Increased circulating fibronectin, depletion of natural IgM and heightened EBV, HSV-1 reactivation in ME/CFS and long COVID, 2023, Liu, Prusty et al

    Yes, there's actually even quite a few studies on this subject. It has been shown that blood plasma levels of cellular fibronectin increase after major trauma resulting in vascular tissue damage, after inflammation, in other diseases such as atherosclerosis, ischaemic heart disease, inflammatory...
  2. E

    Preprint Increased circulating fibronectin, depletion of natural IgM and heightened EBV, HSV-1 reactivation in ME/CFS and long COVID, 2023, Liu, Prusty et al

    That is correct. I guess I got a little bit confused with the selection of different patients. Thanks for correcting me.
  3. E

    Preprint Increased circulating fibronectin, depletion of natural IgM and heightened EBV, HSV-1 reactivation in ME/CFS and long COVID, 2023, Liu, Prusty et al

    Yes. Some ME/CFS patients might also have LC+ME/CFS. Furthermore those patients called HC, never underwent a Covid test, so it isn't even clear how they differ from the no LC group.
  4. E

    Preprint Increased circulating fibronectin, depletion of natural IgM and heightened EBV, HSV-1 reactivation in ME/CFS and long COVID, 2023, Liu, Prusty et al

    To add to that levels of cellular Fibronectin are usually extremely low in plasma and only trace amount of it are detactable in plasma. So it isn't clear to me whether the measurements are mainly statements about cellular of plasma fibronectin. Plasma levels of cellular fibroncetin are known to...
  5. E

    Preprint Increased circulating fibronectin, depletion of natural IgM and heightened EBV, HSV-1 reactivation in ME/CFS and long COVID, 2023, Liu, Prusty et al

    Performs a test of 120 things on a cohort of 12 patients vs 3 controls. Constructs a machine learning classifier based on these results. Says nothing about the accuracy of this classifier amongst this cohort on which is was constructed (which will probably be close to 100% due to the lacking...
  6. E

    Preprint Increased circulating fibronectin, depletion of natural IgM and heightened EBV, HSV-1 reactivation in ME/CFS and long COVID, 2023, Liu, Prusty et al

    The problem I have with this paper is the lack of consistency at different levels. Sometimes they use some ROC analysis to provide some statistical analysis for a certain set, sometimes they do multivariate clustering on a different tiny subset, sometimes they do something different or split the...
  7. E

    Post-COVID sequalae effect in chronic fatigue syndrome: SARS-CoV-2 triggers latent adenovirus in the oral mucosa, 2023, Apostolou, Bragée et al

    The paper has now been published and is accessible https://www.frontiersin.org/articles/10.3389/fmed.2023.1208181/full?utm_source=F-NTF&utm_medium=EMLX&utm_campaign=PRD_FEOPS_20170000_ARTICLE
  8. E

    Trial Report The Psychological Benefits of Forest Bathing in Individuals with Fibromyalgia and CFS/ME: A Pilot Study, 2023, Serrat et al

    Now published - see post #12 I just had to share this study, it's way too funny and a good example of the quality of psychological research. I'm not using the usual formatting here as there's no use to it. It starts of funnily with being published in the European Journal of Forest Research...
  9. E

    Letter: Disrespectful language about patients with long COVID 2023 Pelosi

    Soon you'll be considered to have a psychosomatic illness if you criticise clear flaws in psychosomatic research. The cure for which is of course GET, where your "graded exercise" is the graded acceptance of such flaws.
  10. E

    Serum from Myalgic encephalomyelitis/chronic fatigue syndrome patients causes loss of coherence in cellular circadian rhythms, 2023, Wei et al

    If they are focusing on circadian rhythms I'd be interested in Cortisol readings as well.
  11. E

    The current state of ME/CFS research, and its prospects

    These trials do exist. There was the metformin trial that made big waves and now there's a massive randomized Paxlovid trial (n=2000) looking at the prevention of Long-Covid https://classic.clinicaltrials.gov/ct2/show/NCT05852873?term=Paxlovid&cond=Long-COVID&draw=2&rank=3.
  12. E

    The current state of ME/CFS research, and its prospects

    I agree and that creates even more political and pseudoscientific effort for those wanting to avoid the sceneraio, i.e. those who caused and are causing the situation. There will be larger efforts to dismiss us if liability lawsuits suddenly become a realistic scenario. But I don't want to...
  13. E

    The current state of ME/CFS research, and its prospects

    I think the power structures are particularly relevant. For a large part this means that LC is still viewed as psychosomatic. Admitting that LC is physiological and at the same time can cause ME/CFS at a political level, doesn't only mean that one has neglected and forcefully harmed ME/CFS...
  14. E

    The current state of ME/CFS research, and its prospects

    To me that's more of an artefact on what ME/CFS researchers have decided to be the best solution. Simultaneous research and drug trials has become a much hotter topic than it used to be, the same holds for the Long-Covid field. Drug trials to figure out a biomarker, rather than biomarkers to...
  15. E

    The current state of ME/CFS research, and its prospects

    Logically if Nath would have strong findings in ME/CFS he would have tried to see if the same holds in a similar subset of Long-Covid patients or at least the younger research members in his team would have tried to get grants for this. Their published Long-Covid findings and also the one...
  16. E

    The current state of ME/CFS research, and its prospects

    I'm not getting my hopes up too much on the intramural study. Usually, when researchers really have found some true breakthrough results they try to make that public quicker than is the case here and it doesn't seem like follow-up projects are planned. I think it'll be one of those "we found...
  17. E

    USA: National Institutes of Health (NIH) intramural ME/CFS study

    The message I got was the paper has been submitted for publication (some time in April/May). Which just means that it'll take anywhere from a couple of weeks (probably not since it's a big paper) up to roughly a year for it to be published from that time point onwards. All subsequent...
  18. E

    Post-COVID sequalae effect in chronic fatigue syndrome: SARS-CoV-2 triggers latent adenovirus in the oral mucosa, 2023, Apostolou, Bragée et al

    The post-viral fatigue syndromes long COVID and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) have multiple, potentially overlapping, pathological processes. These include persisting reservoirs of virus e.g. SARS-CoV-2 in long COVID patient's tissues, immune dysregulation with or...
  19. E

    Fighting Post-COVID and ME/CFS – development of curative therapies, 2023, Scheibenbogen et al

    Upps, spelling error. NSGK should be NKSG https://cfc.charite.de/klinische_studien/nksg/. I'll change it above.
  20. E

    Fighting Post-COVID and ME/CFS – development of curative therapies, 2023, Scheibenbogen et al

    I've been told the current platform consists of EndoPAT, RVA, fMRI, a belt test (something for endothelial function) and of course your blood results. So mainly things that look at endothelial dysfunction, which makes sense given their Vericiguat trials. OCT-A doesn't seem to be part of it yet...
Back
Top Bottom